Logo image of VTAK

CATHETER PRECISION INC (VTAK) Stock Fundamental Analysis

NYSEARCA:VTAK - NYSE Arca - US74933X6094 - Common Stock - Currency: USD

0.2416  +0 (+0.67%)

After market: 0.2343 -0.01 (-3.02%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VTAK. VTAK was compared to 187 industry peers in the Health Care Equipment & Supplies industry. VTAK has a bad profitability rating. Also its financial health evaluation is rather negative. VTAK is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VTAK had negative earnings in the past year.
VTAK had a negative operating cash flow in the past year.
VTAK had negative earnings in each of the past 5 years.
VTAK had a negative operating cash flow in each of the past 5 years.
VTAK Yearly Net Income VS EBIT VS OCF VS FCFVTAK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of VTAK (-93.43%) is worse than 78.61% of its industry peers.
VTAK has a Return On Equity of -292.71%. This is amonst the worse of the industry: VTAK underperforms 81.28% of its industry peers.
Industry RankSector Rank
ROA -93.43%
ROE -292.71%
ROIC N/A
ROA(3y)-156.76%
ROA(5y)-139.44%
ROE(3y)-270.77%
ROE(5y)-233.22%
ROIC(3y)N/A
ROIC(5y)N/A
VTAK Yearly ROA, ROE, ROICVTAK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Gross Margin of VTAK (90.02%) is better than 98.40% of its industry peers.
The Profit Margin and Operating Margin are not available for VTAK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VTAK Yearly Profit, Operating, Gross MarginsVTAK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -50K -100K -150K

More info and screens

1

2. Health

2.1 Basic Checks

VTAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VTAK has more shares outstanding
VTAK has a worse debt/assets ratio than last year.
VTAK Yearly Shares OutstandingVTAK Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M
VTAK Yearly Total Debt VS Total AssetsVTAK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

VTAK has an Altman-Z score of -18.38. This is a bad value and indicates that VTAK is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -18.38, VTAK is not doing good in the industry: 89.84% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.01 indicates that VTAK is not too dependend on debt financing.
The Debt to Equity ratio of VTAK (0.01) is better than 67.38% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -18.38
ROIC/WACCN/A
WACC7.56%
VTAK Yearly LT Debt VS Equity VS FCFVTAK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M -30M

2.3 Liquidity

VTAK has a Current Ratio of 0.21. This is a bad value and indicates that VTAK is not financially healthy enough and could expect problems in meeting its short term obligations.
VTAK's Current ratio of 0.21 is on the low side compared to the rest of the industry. VTAK is outperformed by 96.26% of its industry peers.
A Quick Ratio of 0.19 indicates that VTAK may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.19, VTAK is doing worse than 96.26% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.19
VTAK Yearly Current Assets VS Current LiabilitesVTAK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

7

3. Growth

3.1 Past

The earnings per share for VTAK have decreased strongly by -18.23% in the last year.
VTAK shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.57%.
Measured over the past years, VTAK shows a very strong growth in Revenue. The Revenue has been growing by 167.26% on average per year.
EPS 1Y (TTM)-18.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.28%
Revenue 1Y (TTM)9.57%
Revenue growth 3Y167.27%
Revenue growth 5YN/A
Sales Q2Q%74.39%

3.2 Future

VTAK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.08% yearly.
VTAK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 312.31% yearly.
EPS Next Y29.21%
EPS Next 2Y28.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year533.33%
Revenue Next 2Y312.31%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VTAK Yearly Revenue VS EstimatesVTAK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
VTAK Yearly EPS VS EstimatesVTAK Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2023 2024 2025 2026 -20K -40K -60K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

VTAK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VTAK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VTAK Price Earnings VS Forward Price EarningsVTAK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VTAK Per share dataVTAK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

VTAK's earnings are expected to grow with 28.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.08%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

VTAK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CATHETER PRECISION INC

NYSEARCA:VTAK (7/11/2025, 8:04:00 PM)

After market: 0.2343 -0.01 (-3.02%)

0.2416

+0 (+0.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-12 2025-08-12/amc
Inst Owners5.34%
Inst Owner Change0%
Ins Owners2.13%
Ins Owner Change0%
Market Cap3.04M
Analysts85.71
Price Target2.04 (744.37%)
Short Float %31.92%
Short Ratio0.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-52.29%
Min Revenue beat(2)-53.27%
Max Revenue beat(2)-51.31%
Revenue beat(4)0
Avg Revenue beat(4)-66.02%
Min Revenue beat(4)-91.15%
Max Revenue beat(4)-51.31%
Revenue beat(8)0
Avg Revenue beat(8)-67.73%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.54
P/FCF N/A
P/OCF N/A
P/B 0.34
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-9.08
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-0.88
FCFYN/A
OCF(TTM)-0.88
OCFYN/A
SpS0.04
BVpS0.72
TBVpS-1.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -93.43%
ROE -292.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.02%
FCFM N/A
ROA(3y)-156.76%
ROA(5y)-139.44%
ROE(3y)-270.77%
ROE(5y)-233.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.6%
Cap/Sales 11.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.19
Altman-Z -18.38
F-Score3
WACC7.56%
ROIC/WACCN/A
Cap/Depr(3y)3.63%
Cap/Depr(5y)N/A
Cap/Sales(3y)51.53%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.28%
EPS Next Y29.21%
EPS Next 2Y28.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)9.57%
Revenue growth 3Y167.27%
Revenue growth 5YN/A
Sales Q2Q%74.39%
Revenue Next Year533.33%
Revenue Next 2Y312.31%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y62.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y62.89%
OCF growth 3YN/A
OCF growth 5YN/A